Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 2

1(33.3%)

3Total

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06973902Recruiting

The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF

Role: lead

NCT05367037Not ApplicableRecruiting

Physiological Ventricular Pacing Vs Managed Ventricular Pacing for Persistent AF Prevention in Prolonged AV Interval

Role: lead

NCT03428711Phase 2Completed

Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

Role: lead

NCT04329390Completed

MAC Project, Monitoring of AntiCoagulant Therapies (MAC)

Role: lead

NCT05758805Not ApplicableRecruiting

Esophageal Injury of a Tip CF Sensing Ablation Catheter for HP-SD of Paroxysmal and Persistent AF (ESO-SAFE-HP-RF)

Role: lead

NCT04393805Completed

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

Role: lead

NCT04359212Completed

Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19

Role: lead

All 7 trials loaded